Vanguard Group’s C4 Therapeutics CCCC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.32M | Sell |
3,018,022
-352,858
| -10% | -$505K | ﹤0.01% | 3260 |
|
|
2025
Q1 | $5.39M | Buy |
3,370,880
+24,907
| +0.7% | +$39.9K | ﹤0.01% | 3141 |
|
|
2024
Q4 | $12M | Sell |
3,345,973
-24,708
| -0.7% | -$88.9K | ﹤0.01% | 2854 |
|
|
2024
Q3 | $19.2M | Sell |
3,370,681
-186,018
| -5% | -$1.06M | ﹤0.01% | 2606 |
|
|
2024
Q2 | $16.4M | Buy |
3,556,699
+636,671
| +22% | +$2.94M | ﹤0.01% | 2659 |
|
|
2024
Q1 | $23.9M | Buy |
2,920,028
+920,627
| +46% | +$7.52M | ﹤0.01% | 2515 |
|
|
2023
Q4 | $11.3M | Buy |
1,999,401
+74,545
| +4% | +$421K | ﹤0.01% | 2874 |
|
|
2023
Q3 | $3.58M | Buy |
1,924,856
+24,500
| +1% | +$45.6K | ﹤0.01% | 3386 |
|
|
2023
Q2 | $5.23M | Sell |
1,900,356
-212,170
| -10% | -$583K | ﹤0.01% | 3275 |
|
|
2023
Q1 | $6.63M | Buy |
2,112,526
+47,611
| +2% | +$149K | ﹤0.01% | 3171 |
|
|
2022
Q4 | $12.2M | Buy |
2,064,915
+45,261
| +2% | +$267K | ﹤0.01% | 2864 |
|
|
2022
Q3 | $17.7M | Buy |
2,019,654
+58,941
| +3% | +$517K | ﹤0.01% | 2682 |
|
|
2022
Q2 | $14.8M | Sell |
1,960,713
-61,429
| -3% | -$463K | ﹤0.01% | 2788 |
|
|
2022
Q1 | $49.1M | Buy |
2,022,142
+5,683
| +0.3% | +$138K | ﹤0.01% | 2318 |
|
|
2021
Q4 | $64.9M | Buy |
2,016,459
+77,884
| +4% | +$2.51M | ﹤0.01% | 2208 |
|
|
2021
Q3 | $86.6M | Buy |
1,938,575
+531,735
| +38% | +$23.8M | ﹤0.01% | 2061 |
|
|
2021
Q2 | $53.2M | Buy |
1,406,840
+1,018,882
| +263% | +$38.6M | ﹤0.01% | 2339 |
|
|
2021
Q1 | $14.4M | Sell |
387,958
-64,209
| -14% | -$2.38M | ﹤0.01% | 2959 |
|
|
2020
Q4 | $15M | Buy |
+452,167
| New | +$15M | ﹤0.01% | 2783 |
|